Molecular Imaging as a critical tool in discovery of the basis of tumour heterogeneity and developing novel therapies to overcome therapeutic resistance

目前确定癌症的治疗方案依赖于肿瘤沉积物的大小和范围，并结合活检。然而，这种方法无法识别肿瘤进化出对治疗产生或产生耐药性的成分的能力。我的实验室使用先进的分子成像、靶向活组织检查、动物模型和遗传分析来检测和了解这种耐药性的基础，从而开发新的靶向治疗方法来改善患者的预后。

Determining treatment options for cancer currently relies on the size and extent of tumour deposits on imaging, combined with a biopsy. However, this approach fails to recognise the ability of tumours to evolve components that are, or become, resistant to treatment. My laboratory uses advanced molecular imaging, targeted biopsies, animal models and genetic analysis to detect and understand the basis of such resistance and thereby develop new, targeted treatments to improve patient outcomes.